Ckd.Hno
CKD.HNO operates in the Consumer Goods Conglomerates industry, producing and distributing a range of consumer goods products, and generates revenue primarily through the sale of these goods to retail and wholesale customers.
Business. CKD.HNO operates in the Consumer Goods Conglomerates industry, producing and distributing a range of consumer goods products, and generates revenue primarily through the sale of these goods to retail and wholesale customers.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
CKD.HNO operates in the Consumer Goods Conglomerates industry, producing and distributing a range of consumer goods products, and generates revenue primarily through the sale of these goods to retail and wholesale customers.
CKD.HNO has a debt-to-equity ratio of 1.04, indicating a relatively balanced capital structure, though it is leveraged with long-term debt of VND 605.6 billion. The company's liquidity position is assessed as medium, with a current ratio of 1.34, suggesting it can cover its short-term liabilities but with limited buffer. However, the company's operating cash flow is negative at VND -76.96 billion, and free cash flow is also negative at VND -67.99 billion, signaling potential liquidity constraints.
In terms of profitability, CKD.HNO's return on equity (ROE) is 20.91%, which is strong and suggests efficient use of equity capital. The return on assets (ROA) is 7.85%, indicating that the company is generating a moderate return on its total assets. These metrics are in line with the industry's preferred metrics of ROE and ROA, and the company appears to be performing well relative to the cohort median.
CKD.HNO's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic breakdown provided in the available data. This lack of diversification could pose a risk if the company's primary market experiences a downturn. The company's exposure to a single segment may also limit its ability to adapt to changing market conditions.
The company's growth trajectory is uncertain, as the outlook for the current fiscal year does not provide specific numeric deltas for revenue or earnings. However, the company's capital expenditure of VND -140.15 billion suggests a significant investment in its operations, which could support future growth. The absence of detailed growth projections makes it difficult to assess the company's long-term potential.
The risk assessment for CKD.HNO indicates a medium liquidity risk, primarily due to its negative operating and free cash flows. The company's dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the company's net cash position is negative after subtracting total debt, which could impact its financial flexibility.
Recent events and filings for CKD.HNO are not detailed in the available data, making it difficult to assess any recent developments that may impact the company's financial position. The company's financial statements do not provide information on recent strategic initiatives or operational changes.
- CKD.HNO has a strong return on equity (20.91%) and a moderate return on assets (7.85%), indicating efficient use of equity and assets.
- The company's debt-to-equity ratio is 1.04, suggesting a balanced capital structure but with a notable level of long-term debt.
- CKD.HNO's liquidity position is medium, with a current ratio of 1.34, but its negative operating and free cash flows may pose liquidity constraints.
- The company's revenue is concentrated in a single business segment, which could increase its exposure to market-specific risks.
- The company's growth trajectory is uncertain, with no detailed projections provided for the current or next fiscal year.
- CKD.HNO's dilution risk is low, and there are no significant dilution sources identified in the available data.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- CKD.HNO Market data — financials · 2026-05-27